Stay updated on Pembrolizumab Post-Surgery in MSI-H Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-Surgery in MSI-H Solid Tumors Clinical Trial page.

Latest updates to the Pembrolizumab Post-Surgery in MSI-H Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new site revision (v3.4.2) has been added, and the older revision (v3.4.1) along with the government funding status notice have been removed. These are administrative page maintenance updates and do not modify study details, eligibility criteria, or results.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about potential data inaccuracy due to funding issues has been added, and the page version was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded 'Show glossary' and the 'Last Update Submitted that Met QC Criteria' label, and updated footer notes to 'No FEAR Act Data' and 'Revision: v3.4.0'. Removed the previous 'Last Update Submitted that met QC Criteria' label, 'No FEAR Act data' note, and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check42 days agoChange DetectedThe change is a minor metadata update (Revision: v3.3.4 added; v3.3.3 removed) that does not affect study content or user-visible information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section with New Jersey and New York headings and removed the separate New Jersey Locations and New York Locations subsections. Revision updated from v3.3.2 to v3.3.3.SummaryDifference0.3%

- Check92 days agoChange DetectedPublications attribution text updated to indicate automatic population from PubMed, and the revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-Surgery in MSI-H Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Surgery in MSI-H Solid Tumors Clinical Trial page.